What Sets CTMC Apart?

By uniting biotech partners, robust manufacturing, and MD Anderson’s world-class clinical trial expertise, CTMC creates a collaborative path from discovery to treatment.

Accelerating Innovation: helping emerging biotechs de-risk development and reach clinical proof-of-concept faster.

Integrated Expertise: process and analytical development, GMP manufacturing, logistics, and regulatory support under one roof.

Proven Partnership: established in 2022 as a joint venture between Resilience + MD Anderson Cancer Center.

Purpose-built Facility: state-of-the-art 60,000 SF GMP space designed for speed, flexibility, and scalability.

Mission-driven: bridging early innovation and commercial readiness with efficiency, purpose, and patient focus.

Patient-adjacent Model: based in the Texas Medical Center, in close collaboration with MD Anderson clinicians, researchers, and trial infrastructure.

CTMC Mission Statement

Through our people, platforms, and partnerships, we create disruptive manufacturing solutions enabling impactful cell therapies to reach patients.

Purpose-driven

Our shared mission to bring transformative therapies to patients is grounded in trust, transparency, and integrity.

Intention

We act with drive and clarity to ensure every decision advances our mission and delivers meaningful impact.

Grit

We embrace challenges with tenacity and fortitude, turning obstacles into progress through hard work and perseverance.

Nimble

We adapt with speed and agility—responding to change with innovation and staying ahead in a fast-moving field.

Less than 1,500 steps from
MD Anderson – where innovation meets patient care.

Being co-located in the Texas Medical Center enables efficient material transfer, faster turnaround times, and seamless clinical coordination—all critical for cell therapy manufacturing.

Parent Companies

MD Anderson
Cancer Center

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world’s most respected centers focused on cancer patient care, research, education, and prevention. The institution’s mission is to eliminate cancer in Texas, the nation, and the world.

Learn More

National Resilience

Founded in 2020, Resilience is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives and protect biopharmaceutical supply chains against future disruptions.

Learn More

SQUARE FEET DEDICATED TO CELL THERAPY

cGMP CLEANROOMS

SQUARE FEET OF SUPPORTING LABS

A Proven Team Driving Scalable, Capital-Efficient Execution +

CTMC brings together seasoned industry leaders and academic innovators to accelerate cell therapies from preclinical development through clinical proof of concept while reducing risk, shortening timelines, and preserving partner capital.

Jason has over twenty years of research and leadership experience in pharmaceuticals and biotech creating new divisions and companies from the ground up. He sits on several scientific advisory boards. He has a BS in Biology and PhD in Molecular and Cellular Physiology.

Jason Bock

Co-Founder + CEO

Houman has spent over twenty years building and leading domestic and international teams in both product development and business roles. Houman holds an MSc in Molecular Biology and an MBA.

Houman Mesghali

Co-Founder + COO

Amy is a seasoned leader in global oncology strategy, transactions, and program implementation, with expertise in forging high-value partnerships across health systems, governments, and industry leaders. She has a Masters of Healthcare Administration.

Amy Hay

Chief Business Officer

Duane has more than 25 years of quality leadership in biotechnology focused on compliance, team building, and innovative cell therapy operations. Duane has a Lean Six Sigma Black Belt and a BS in Chemical Engineering.

Duane Avant

Chief Technical Officer

Priya has vast experience in analytical development supporting the product pipeline from pre-clinical to late-stage cancer therapeutics across multiple modalities including small molecules and cell therapy. She has a B.Tech in Chemical Engineering and a PhD in Chemical and Biomolecular Engineering.

Priya Balasubramanian

Head of Quality Control + Analytical Development

Chantale has a PhD in Immunology and more than 20 years of experience in the fields of immunology and T-cell therapy, including academia and biotech work in TIL and CAR-T biology, process development, and manufacturing. She holds four patents on TIL/adoptive cell therapy.

Chantale Bernatchez

Head of Process Development

Teresa has over 25 years of QA experience in the biotech, pharmaceutical, and medical device industries. With expertise in developing quality systems and leading quality operations from clinical through commercial manufacturing, she is known for effectively collaborating with cross-functional teams to ensure cGMP compliance, regulatory readiness, and operational excellence. Teresa holds a BS in Chemistry.

Teresa Collazo

Head of Quality Assurance

Jane has extensive experience working with cross-functional teams to generate effective regulatory strategies and high-quality regulatory submissions. She has provided strategy and documentation for products across all stages of development, from preclinical to commercial. Jane has a BS in Biology and a PhD in Biological Sciences.

Jane Koo

Head of Regulatory Affairs

Tamara has nearly two decades of experience in cell and gene therapy and immuno-oncology spanning discovery, pre-clinical development, and clinical translation. With a dual PhD in Immunology and Molecular Genetics, plus a strong background in strategic development, Tamara has driven the development of multiple CGT assets through partnerships with pharma and biotech worldwide.

Tamara Laskowski

Head of Biotech Partnerships + Strategy

Laine has almost 20 years of experience in the pharmaceutical industry, 13 years of which are directly with Cell Therapy and Viral Vector. Laine holds a BS in Biology.

Laine Linden

Head of Technical Operations

Erin has more than 20 years of combined research and biotech experience. Erin holds 11 biotherapeutic-related patents and has a BS in Chemistry and a PhD in Biochemistry.

Erin K. Willert

Head of Project + Alliance Leadership

Board Of Managers +

Jason is the CEO and Co-Founder of CTMC. He has over 20 years of research and leadership experience in pharmaceuticals and biotech, creating new divisions and companies from the ground up. He serves on several scientific advisory boards.

Jason Bock, PhD

Co-Founder + CEO
CTMC

Giulio is Senior VP and Chief Scientific Officer at MD Anderson Cancer Center. He is Professor and Sewell Distinguished Family Chair in the Department of Genomic Medicine, with a joint appointment in the Department of Molecular and Cellular Oncology.

Giulio Draetta, MD, PhD

Chief Scientific Officer
MD Anderson Cancer Center

Ferran is Senior VP of Research Administration and Industry Relations at MD Anderson Cancer Center. He leads the institution’s efforts to generate strategic collaborations that bring new drugs, diagnostics, and technologies forward to more quickly benefit patients with cancer.

Ferran Prat, JD, PhD

Chief Commercial Officer
BostonGene

Ori has provided general corporate representation to a variety of organizations in diverse industries with an emphasis on emerging companies. Most recently he was Co-Chair of the Emerging Companies and Venture Capital practice at Morrison & Foerster LLP in Boston.

Ori Solomon, JD

Executive Vice President
Chief Legal + Administrative Officer
Resilience

What Sets CTMC Apart?